No Data
No Data
Harbin Air Conditioner Co., Ltd. Interim Report 2024
Summary of Half-Year Report of Harbin Air Conditioner Co., Ltd. in 2024.
Harbin air conditioning (600202.SH): net income of 8.9 million yuan in the first half of the year, a year-on-year decrease of 42.98%.
Harbin Air Conditioning (600202.SH) released its semi-annual report on August 14. During the reporting period, the company achieved a revenue of 708.5704 million yuan, a 1.02% increase from the same period last year; the main business income was 706.2471 million yuan, a 1.09% increase from the same period last year; and the other business income was 2.3233 million yuan (sales materials, etc.), a 16.72% decrease from the same period last year. Among them, the revenue from the main business of power station air-cooled products was 195.2183 million yuan, a 485.92% increase from the same period last year; and the revenue from petrochemical products was 44,378.
Express News | Liu Mingshan, the chairman and shareholder of Harbin Air Conditioning, is under disciplinary investigation and supervision.
Express News | Harbin Air Conditioning: Chairman and controlling shareholder Liu Mingshan has been placed under investigation.
Harbin Air Conditioning (600202.SH): The holding subsidiary Toyamagawa Biotechnology Development Co., Ltd. has no reserves of synthetic biology-related technology
Gelonghui, May 17丨Harbin Air Conditioning (600202.SH) said on an interactive platform that in 2023, the company will further explore the international market and add a number of international contracts and multinational enterprise contracts; using the advantages of new products and technology, it has made major breakthroughs in the transformation of old power plants, energy saving and emission reduction upgrades, and has many technical reserves, forming a business model where new construction and transformation go hand in hand. In 2023, the international market (export) order amount was equivalent to about RMB 336.933 million, an increase of 541.50% over the previous year. Toyamagawa Biotechnology Development Co., Ltd., a holding subsidiary of the company, did not synthesize
No Data